68GaNOTA-Anti-MMR-VHH2
- Generic Name
- 68GaNOTA-Anti-MMR-VHH2
Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 20
- Registration Number
- NCT05933239
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Jette, Brussel, Belgium
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
Phase 2
Recruiting
- Conditions
- Hodgkin Lymphoma, AdultNon Hodgkin LymphomaSolid Malignancy Located in the Head and NeckCancerAtherosclerosis of ArteryCardiac SarcoidosisSarcoidosisCarotid StenosisHLH
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 140
- Registration Number
- NCT04758650
- Locations
- 🇧🇪
Uz Brussel, Brussels, Brussel, Belgium
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
Phase 1
Completed
- Conditions
- Malignant Solid TumorMelanoma (Skin)Breast Cancer
- Interventions
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 13
- Registration Number
- NCT04168528
- Locations
- 🇧🇪
Uz Brussel, Brussels, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath